Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025

Werewolf Therapeutics, Inc.

2025-Q1 EPS reported -$0.40

Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.
Cash and equivalents $92.0M as of March 31, 2025; runway into Q4 2026.
WTX-124 Phase 1/1b on track for interim data and FDA regulatory discussions in H2 2025.
First patient dosed in WTX-330 Phase 1b/2 trial; initial Phase 1 data showed clinical activity and tolerability.
INDUCER T cell engager development candidate expected by end of Q2 2025; PREDATOR masking shown to silence peripheral activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.